Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:57:47.097Z.
Calculation as of: 2026-10-06T17:57:47.097Z.
Quote observation: 2026-10-06T17:55:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66afd7ad6fe085f612ae866be6517f9e897c4fba6e73e474a8e5d595bf17d99d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$3.39B
Price/OCF Ratio
17.46
TTM Avg
27.05
3Y Avg
38.50
5Y Avg
38.50
Market Cap
$3.19B
Price/OCF Ratio
40.02
TTM Avg
41.06
3Y Avg
41.06
5Y Avg
377.72
Market Cap
$3.48B
Price/OCF Ratio
N/A
TTM Avg
11.75
3Y Avg
11.73
5Y Avg
11.73
Market Cap
$3.49B
Price/OCF Ratio
N/A
TTM Avg
627.91
3Y Avg
627.91
5Y Avg
627.91
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.33B | N/A | N/A | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.35B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 17.46 | 27.05 | 38.50 | 38.50 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.41B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.42B | 36.47 | 25.34 | 102.30 | 213.86 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 40.02 | 41.06 | 41.06 | 377.72 |
| Celcuity Inc. (CELC)vs › | $3.48B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A | 11.75 | 11.73 | 11.73 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.49B | N/A | 627.91 | 627.91 | 627.91 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.49B | N/A | 14.77 | 14.77 | 14.77 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
